12 research outputs found
Outcome of patients with PLA2R-related PMN.
<p>Outcome of patients with PLA2R-related PMN.</p
Comparison of disease progression between patients with PLA2R-Ab ≤ 97.6 RU/ml and > 97.6 RU/ml.
<p>Comparison of disease progression between patients with PLA2R-Ab ≤ 97.6 RU/ml and > 97.6 RU/ml.</p
Comparison of the clinical features between patients with PLA2R-related PMN achieving or not achieving spontaneous remission.
<p>Comparison of the clinical features between patients with PLA2R-related PMN achieving or not achieving spontaneous remission.</p
Characteristics of patients with primary and secondary MN.
<p>Characteristics of patients with primary and secondary MN.</p
Comparison of patients with PLA2R-related and PLA2R-unrelated PMN.
<p>Comparison of patients with PLA2R-related and PLA2R-unrelated PMN.</p
Predictors of evolution to stage ≥4 CKD in patients with PLA2R-related PMN.
<p>Predictors of evolution to stage ≥4 CKD in patients with PLA2R-related PMN.</p
Kaplan-Meier plots of the risk of disease relapse following rituximab in 31 IgG4-RD responding patients.
<p>Kaplan-Meier plots of the risk of disease relapse following rituximab in 31 IgG4-RD responding patients.</p
Kaplan-Meier plots of the risk of disease relapse following rituximab for patients with IgG4-RD RI >9 and with IgG4-RD RI ≤9 at RTX treatment.
<p>IgG4-RD RI, IgG4-related disease Responder Index.</p
Clinical, biological and radiological efficacy of RTX in 33 patients with IgG4-RD.
<p>Clinical, biological and radiological efficacy of RTX in 33 patients with IgG4-RD.</p
Hazard ratio for risk of flare: Unadjusted Cox regressions.
<p>Hazard ratio for risk of flare: Unadjusted Cox regressions.</p